Inhalation of endothelin receptor blockers in pulmonary hypertension.
Endothelin 1 (ET-1) is a potent pulmonary vasoconstrictor and mediator of lung diseases. Antagonism of the ET-1-mediated effects has become an important therapeutic approach. ET-1 (A and B) receptors are differentially distributed in the lung vasculature. Whereas the ET(A) receptors mainly mediate vasoconstriction, the endothelial ET(B) receptor seems to have vasodilative properties. We sought to determine if antagonism of ET receptors can be achieved by inhalation of specific blockers in a model of ET-1-mediated pulmonary hypertension.
Leuchte
Hanno H
HH
Division of Pulmonary Diseases, Department of Internal Medicine I, Ludwig Maximilians University, Klinikum Grosshadern, Munich, Germany. Hanno.Leuchte@med.uni-muenchen.de
Meis
Tobias
T
El-Nounou
Michal
M
Michalek
Jens
J
Behr
Jürgen
J
D000280:Administration, Inhalation; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000494:pharmacology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D009842:Oligopeptides / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D011654:Pulmonary Edema / Q000517:prevention & control; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D009842:Oligopeptides; D010456:Peptides, Cyclic; D010880:Piperidines; D014662:Vasoconstrictor Agents; C086539:BQ 788; C072247:cyclo(Trp-Asp-Pro-Val-Leu)